---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-026696"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2026-06-01T23:40:29+00:00"
generated_at: "2026-06-02T10:16:21.703539+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Lantern Pharma uses presentation to discuss Harmonic Phase 2 trial of LP-300

## Summary
- Presentation furnished as Exhibit 99.1 on June 1, 2026, regarding LP-300 in Harmonic Phase 2 trial.
- No specific trial results or financial data disclosed in the 8-K filing itself.
- Investors must review the presentation exhibit for detailed clinical updates.

## SEC filing metadata
- accession: 0001493152-26-026696
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2026-06-01T23:40:29+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315226026696/0001493152-26-026696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315226026696/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-026696
- JSON: https://secwatch.observer/filing/0001493152-26-026696.json
- Plain text: https://secwatch.observer/filing/0001493152-26-026696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.